Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Thumbnail Image

Files

CCR-16-1137_de Bono.pdf (302.83 KB)

Embargo End Date

ICR Authors

Sharp, Adam
 De Bono, Johann

Authors

Sharp, A
Welti, J
Blagg, J
de Bono, JS

Document Type

Journal Article

Date

2016-09-01

Date Accepted

2016-05-26

Abstract

Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.

Citation

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 22 (17), pp. 4280 - 4282

DOI

10.1158/1078-0432.ccr-16-1137

URI

https://repository.icr.ac.uk/handle/internal/464

Rights

https://www.rioxx.net/licenses/all-rights-reserved

Source Title

Publisher

AMER ASSOC CANCER RESEARCH

ISSN

1078-0432

eISSN

1557-3265

Collections

Cancer Therapeutics
Clinical Studies

Research Team

Medicinal Chemistry 1
Prostate Cancer Targeted Therapy Group
Translational Therapeutics

Notes